{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"The number of patients with clinical responses (CR, VGPR, PR, or minimal response \\[MR\\]) will be summarized by stage.","groups":[{"description":"Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)","id":"OG000","title":"Phase I: Stage 1 (MV-NIS Alone)"},{"description":"Patients receive 10 mg/kg cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)","id":"OG001","title":"Phase I: Stage 2 (MV-NIS and Cyclophosphamide)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Per protocol, Phase I specified secondary endpoint is evaluated for each STAGE independently; thus, the stage 1 dose level groups were combined and the stage 2 dose level groups were combined for this analysis PER PROTOCOL.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Number of Patients With Clinical Responses (Phase I)","type":"SECONDARY","unitOfMeasure":"Participants"}